Catheter Precision, Inc.(VTAK)Earnings, Financials & Key RatiosCatheter Precision, Inc. (VTAK) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's liquidity position is critical, with a cash balance of only $441,000 as of 2026Q1, which appears insufficient to support ongoing operations without immediate and potentially dilutive external financing.
Catheter Precision, Inc. (VTAK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Catheter Precision, Inc. (VTAK) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 18, 2026 | $1.39vs $20.90+93.3% | $432,000vs $2M-73.0% |
| Q2 2026 | Mar 31, 2026 | $1.53vs $20.90+107.3% | $238,000vs $2M-86.0% |
| Q4 2025 | Nov 13, 2025 | $1.70vs $26.60+93.6% | $226,000vs $1M-81.2% |
| Q3 2025 | Aug 11, 2025 | $7.22vs $34.20+78.9% | $212,000vs $600,000-64.7% |
Recent stock market news and headlines for Catheter Precision, Inc. (VTAK)
Every FLYTE aircraft combines the Cirrus Vision Jet's CAPS whole-aircraft parachute and Safe Return Emergency Autoland with onboard LifeVac life-saving equipment .
Revenue Increased Sequentially Approximately 170% from Q1 to Q2 (QoQ) as Customer Adoption Accelerates Across Key Travel Markets Revenue Increased Sequentially Approximately 170% from Q1 to Q2 (QoQ) as Customer Adoption Accelerates Across Key Travel Markets
Key metrics vs top competitors for Catheter Precision, Inc. (VTAK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.71 | $1.56B | -0.04 | 95% | -2098.05% | -186.69% | — | |
| $32.80 | $1.66B | -136.67 | 14.88% | -0.83% | -0.95% | — | |
| $0.66 | $22.7M | -1.06 | — | — | -1034.04% | — | |
| $125.09 | $4.11B | -89.99 | 26.24% | -3.53% | -20.6% | — | |
| $45.70 | $378.4M | 53.14 | 16.97% | 14.08% | 22.14% | — | |
| $45.30 | $67.33B | 23.35 | 19.87% | 17.23% | 14.67% | — |
Catheter Precision, Inc. (VTAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Catheter Precision, Inc. (VTAK) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 18, 2026·SEC
Apr 23, 2026·SEC
Apr 15, 2026·SEC
Get notified when VTAK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Catheter Precision, Inc. (VTAK) stock FAQ — growth, dividends, profitability & financials explained
Catheter Precision, Inc. (VTAK) reported $1.1M in revenue for fiscal year 2025. This represents a 81% decrease from $6.0M in 2016.
Catheter Precision, Inc. (VTAK) grew revenue by 95.0% over the past year. This is strong growth.
Catheter Precision, Inc. (VTAK) reported a net loss of $14.8M for fiscal year 2025.
Catheter Precision, Inc. (VTAK) has a return on equity (ROE) of -186.7%. Negative ROE indicates the company is unprofitable.
Catheter Precision, Inc. (VTAK) had negative free cash flow of $8.8M in fiscal year 2025, likely due to heavy capital investments.
